The Health Ministry’s Commission for the Formation of Lists of Vital and Essential Drugs and High-Care Drugs reviewed nine drugs proposed for inclusion in the Vital and Essential Drugs List. As a result, four drugs have been approved: zanubrutinib, polatuzumab vedotin, nurulimab + prolgolimab, and a new form of daratumumab for subcutaneous administration, which has also been included in the list of cost-intensive drugs for specific conditions.
However, five drugs were not approved, and the decision on the other two was postponed until next week. This meeting was one of a series of four meetings scheduled for the end of August, during which other drugs will also be considered. The meetings are scheduled for August 23, 27 and 28.
